The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world homologous recombination repair mutation (HRRm) testing patterns in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in the United States.
 
Daniel J. George
Leadership - Capio BioSciences
Honoraria - American Association for Cancer Research; AstraZeneca; Aveo; Axess Oncology; Bayer; Eisai; EMD Serono; Exelixis; IDEOlogy Health; Janssen Oncology; Medscape; Merck; Millennium Medical Publishing; Myovant Sciences; Nektar; Novartis; OncLive; Pfizer; Propella Therapeutics; Sanofi; Seagen; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Constellation Pharmaceuticals; Exelixis; Janssen; Merck Sharp & Dohme; Michael J. Hennessy Associates; Myovant Sciences; Novartis; Pfizer; Physicans' Education Resource; Propella Therapeutics; RevHealth; Sanofi; Xcures
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Expert Testimony - Exelixis
Travel, Accommodations, Expenses - Bayer; Exelixis; Novartis; Pfizer
 
Furaha Kariburyo-Yay
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Daiichi Sankyo/UCB Japan (Inst); Incyte (Inst); Merck (Inst); Regeneron (Inst)
 
Himani Aggarwal
Employment - Lilly; Lilly (I); Merck
Stock and Other Ownership Interests - Daiichi Sankyo (I); Lilly; Lilly (I); Merck
Research Funding - Lilly; Lilly (I); Merck
 
Jon G. Tepsick
Employment - ConcertAI
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EQRx (Inst); Gilead Sciences (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Regeneron (Inst); Sandoz (Inst)
 
Rebekah Yu
Research Funding - Merck (Inst)
 
Weiyan Li
Employment - AstraZeneca; AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Kimmie K. McLaurin
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Chinelo Orji
Employment - Merck
 
Lincy S. Lal
Employment - ConcertAI; Optum/UnitedHealth Group
Stock and Other Ownership Interests - Concertai
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo/UCB Japan (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Oncology (Inst); Kyowa Kirin International (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst); Sandoz (Inst); Teva (Inst)
 
Sameer R. Ghate
Employment - Merck Sharp & Dohme; Novartis
Stock and Other Ownership Interests - Advaxis (I); Agenus (I); Mannkind; Pfizer (I); Provectus